SCHEMBL14830665

SCHEMBL14830665

CCCCOC(=O)N(CC(=O)N(C)OC)c1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
MCL1 Q07820 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
POLB P06746 1/20 0.40
BCL2A1 Q16548 2/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14831388 0.79 RAB9A (0.45) RAB9AALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL14830095 0.79 MT-CO2 (0.44) RAB9ACHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL3650581 0.77 ALDH1A1 (0.43) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL3661310 0.73 KEAP1 (0.49) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL6266590 0.72 SMN1; SMN2 (0.49) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL3656769 0.71 TSHR (0.51) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL29001248 0.71 NPC1 (0.52) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL6717574 0.71 TSHR (0.49) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL8773038 0.70 ALDH1A1 (0.50) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL11866005 0.69 ALDH1A1 (0.43) RAB9AALDH1A1SMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760845-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2014-08-06 EP disclosed
WO-2013049250-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2013-04-04 WO disclosed